Exicure, Inc.
8045 Lamon Avenue
Suite 410
Skokie
Illinois
60077
United States
Tel: 847-673-1700
Fax: 847-556-6411
Website: http://www.exicuretx.com/
86 articles with Exicure, Inc.
-
Clinical Catch-Up: September 14-18
9/21/2020
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies. -
Exicure announced positive results from its Phase Ib trial evaluating cavrotolimod, its SNA-enabled TLR9 agonist, that is being developed for the treatment of solid tumors, in combination with pembrolizumab.
-
Exicure Presents Promising Interim Results from Ongoing Phase 1b/2 Trial of Cavrotolimod at Virtual KOL Event Today
9/16/2020
Confirmed overall response rate (ORR) of 21% in the dose-escalation stage across all doses, confirmed ORR 33% at the highest and selected Phase 2 dose Target tumor shrinkage was observed in 37% of patients Preliminary data show activity in patients with melanoma, Merkel cell carcinoma (MCC), and cutaneous squamous cell carcinoma (CSCC) Phase 2 arms in both MCC and CSCC are currently recruiting CHICAGO & CAMBRIDGE,
-
Exicure to Present at Upcoming Conferences
9/10/2020
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced presentations at the following conferences during the month of September: TIDES: Oligonucleotide & Peptide Therapeutics Panel discussion: The impact of technological advances in the TIDES Space Presented by: CEO David Giljohann Tue
-
Exicure Announces a Virtual KOL Meeting to Discuss Preliminary Phase 1b Efficacy Data for Cavrotolimod
8/25/2020
Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, announced that it will host a virtual KOL meeting on Wednesday, September 16th, 2020 from 10:30 am-12 pm ET to discuss the preliminary Phase 1b efficacy and safety data for cavrotolimod, Exicure’s SNA-enabled TLR9 agonist for solid tumors.
-
Exicure, Inc. Reports Second Quarter 2020 Financial Results and Corporate Progress
8/12/2020
Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported financial results for the quarter and six months ended June 30, 2020 and provided an update on corporate progress.
-
Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference 2020
8/5/2020
Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that David Giljohann, CEO, will present a Fireside Chat at the BTIG Virtual Biotechnology Conference 2020 on Monday, August 10, 2020. Date: Monday, August 10, 2020 Time: 1:30 PM Eastern Time Location: Virtual Webcast The presentation wi
-
Exicure, Inc. Added to Russell 2000® Index
6/29/2020
Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, announced that it has been added to the Russell 2000® index.
-
Exicure Presents Cavrotolimod (AST-008) Clinical Data at AACR 2020 Virtual Meeting
6/22/2020
Poster presentation of pharmacodynamic and safety data of cavrotolimod (AST-008) from Exicure’s ongoing Phase 1b/2 clinical trial in solid tumor patients
-
Exicure, Inc. to Present at the 2020 BMO Prescription for Success Healthcare Conference
6/18/2020
Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that Dr. David Giljohann, Chief Executive Officer of Exicure, will present a corporate update at the virtual 2020 BMO Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 4:30 p.m. EDT.
-
Exicure Announces First Patient Dosed in Phase 2 Merkel Cell Carcinoma Trial of Cavrotolimod (AST-008)
6/16/2020
Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced the dosing of the first patient enrolled in the Phase 2 dose expansion stage of the cavrotolimod Phase 1b/2 clinical trial.
-
Exicure, Inc. to Present at Jefferies 2020 Healthcare Conference
5/20/2020
Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that Dr. David Giljohann, Chief Executive Officer of Exicure, will present at the virtual Jefferies 2020 Healthcare Conference on Thursday, June 4, 2020 at 1:00 p.m. EDT.
-
Exicure Announces Appointment of Dr. Douglas E. Feltner as Chief Medical Officer
5/19/2020
Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that it has appointed Douglas E. Feltner, M.D. as its Chief Medical Officer effective May 18th, 2020.
-
Exicure to Present Clinical Data at AACR 2020 Virtual Meeting
5/15/2020
Poster presentation will show updated pharmacodynamic and safety data of AST-008 from Exicure’s ongoing Phase 1b/2 study
-
Exicure, Inc. Reports First Quarter 2020 Financial Results and Corporate Progress
5/14/2020
Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, reported financial results for the quarter ended March 31, 2020 and provided an update on corporate progress.
-
Exicure to Present at the American Society of Clinical Oncology 2020
5/14/2020
Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, will present a poster at the 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place virtually from May 29-31. The ASCO poster, by Dr. Mohammed Milhem of the University of Iowa and coauthors, titled “AST-008: A Novel Approach to TLR
-
Exicure to Present AST-008 Updates at 2020 AACR Virtual Annual Meeting
5/5/2020
Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, will present at the American Association of Cancer Research Virtual Annual Meeting II, occurring June 22 – 24, 2020.
-
Exicure, Inc. Announces Appointment of Timothy P. Walbert as Chairman of the Board
4/7/2020
Exicure, Inc. reported Timothy P. Walbert, Chairman, President and CEO of Horizon Therapeutics plc, will succeed Chad Mirkin, Ph.D. as Chairman of Exicure’s Board of Directors.
-
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 31, 2020.